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The study examined potential changes in the proportion of metabolic health according to
body size categories over time and across strata of sex and age, varying definitions of meta-
bolic health.
Methods
We analysed data from national health interview and examination surveys 1997–99 and
2008–11 for adults aged 18–79 years (GNHIES98: N = 6,565; DEGS1: 6,860). Metabolic
health as defined by ATPIII criteria was examined across body mass index categories. The
Plourde and Karelis criteria were applied in relation to abdominal obesity.
Results
Proportions of adults with metabolic health by body size categories were largely stable over
time, except for an increasing proportion of metabolically healthy persons with pre-obesity
and metabolically healthy women without abdominal obesity. In both surveys proportions of
adults meeting ATPIII criteria ranged from approximately 30% among men and women with
obesity, to about two thirds of those with pre-obesity to about 93% among those with normal
weight. According to Plourde and Karelis criteria proportions ranged from almost 30%
among men and women without abdominal obesity to less than 10% among those with
abdominal obesity. Proportions were consistently higher among younger than older age
groups and less consistently higher among women than men.
Conclusions
Proportions of adults with metabolic health by body size categories were largely stable over
time, except for an increasing proportion of metabolically healthy women without abdominal
obesity. There is no evidence that metabolic health among adults with obesity increased in
Germany over a period of ten years.
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Introduction
Worldwide obesity increased from 1975 to 2014 [1] and the prevalence of obesity in Germany
also increased over the first decade of the 21st century, especially among young adults [2].
While obesity is closely related to clustering of metabolic risk factors and increased morbidity
and mortality risk [3], a substantial proportion of persons with obesity do not fulfil commonly
applied cut-off criteria to define adverse metabolic risk profiles in cross-sectional epidemiolog-
ical studies. This has fuelled discussion on whether there may be a metabolically more benign
or metabolically healthy (MH) subgroup of persons with obesity with a better prognosis than
metabolically unhealthy (MU) persons [4]. Vice versa, normal weight persons already express
cardio-metabolic risk factor clustering, and this normal weight MU subgroup may be at high
risk of morbidity and mortality in the absence of obesity [5]. Previous studies reported a highly
variable proportion of MH people with obesity ranging from 10 to 40% based on varying crite-
ria to define the metabolic syndrome (MetS) and insulin sensitivity [6, 7]. However, there is
ongoing controversy regarding the public health relevance of MH in the presence of obesity [8,
9], since it may shift the focus away from the major problem of an increasing prevalence of
obesity [10]. Furthermore, recent meta-analyses suggest that MH persons with obesity have an
intermediate metabolic health status with increased risk for cardiovascular disease (CVD) [11]
and mortality [12] compared to MH normal weight persons, but lower risk compared to MU
persons with obesity.
The mechanisms to explain the favourable metabolic profile of MH persons with obesity
are still unknown, but seem to be associated with the individual fat distribution [4]. A more
favourable fat distribution with more subcutaneous and less visceral adipose tissue could be
determined by genetic [13], as well as behavioural and environmental factors [14]. Recent
analyses of national health studies in Germany 1997–1999 (GNHIES98) and 2008–11
(DEGS1) demonstrated favourable changes in several cardio-metabolic risk factors [15–18],
albeit not in high blood pressure also including blood pressure treatment [19]. In the US [20]
and northern Sweden [21] CVD risk factors except diabetes have improved, and population-
based data from Denmark demonstrated an upward shift towards higher values of optimal
body mass index (BMI) associated with lowest mortality from all and cardiovascular causes
[22]. Therefore it remains unclear if the prevalence of MH obesity has changed over time.
Against this background, the present study aimed: (1) to investigate potential changes in
the proportion of MH according to body size categories over time using comparable data from
the two recent National Health Interview and Examination Surveys for adults in Germany, (2)
to examine if the changes were consistent across strata of sex and age.
Methods
Study design and population
The National Health Interview and Examination Surveys for adults in Germany 1997–99
(GNHIES98) and 2008–11 (DEGS1) were conducted as part of the German health monitoring
system. In a two-stage sampling procedure 180 sample-points (study locations) were selected
reflecting the distribution of the population at the regional level. Then age- and sex-stratified
random samples of the population 18–79 years were selected from population-registries in
every sample point. For DEGS1 the sample consists of 4,193 first-time participants and 3,959
persons, who had already participated in GNHIES98. The concept of both surveys is described
in detail elsewhere [23, 24]. The response rate was 61% in GNHIES98, 62% for re-participants
in DEGS1 and 42% for first-time participants in DEGS1. Non-participants were asked to fill in
a short questionnaire including information on socio-demographic and health-related
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characteristics. The comparison between responders and non-responders of DEGS1 and
between the overall net sample and the resident population of Germany supported high repre-
sentativeness [25].
The net sample of 7,124 participants for GNHIES98 and 7,115 participants for DEGS1 had
participated in the examination part and allows representative cross-sectional analyses for the
age range of 18–79 years and time trend analyses. Participants with missing data on the defini-
tion of MH and body size category were excluded, resulting in a final study sample of 6,565 for
GNHIES98 and 6,860 for DEGS1. Both studies were conducted according to the Federal and
State Commissioners for Data Protection guidelines. DEGS1 was approved by the local ethics
committee at Charité-Universitätsmedizin Berlin in October 2008 (ethics approval application
document number: EA2/047/08). The implementation of the surveys conforms to the princi-
ples of the Helsinki Declaration. All participants provided written informed consent prior to
survey participation.
Data collection and study variables
Standardized measures of body weight, height, and waist circumference (WC) were obtained
from participants wearing light clothing without shoes (GNHIES98) or underwear without
shoes (DEGS1). Body weight was measured using a calibrated electronic scale (SECA, column
scale 930) with a precision of 0.1kg. In GNHIES98 body height was measured with a leveling
board on the electronic scale and in DEGS1 with a portable stadiometer (Holtain Ltd., UK),
both with a precision of 0.1 cm. The body mass index (BMI) was calculated using the formula:
BMI [kg/m2] = body weight [kg]/body height [m]. WC was measured at the minimal waist
using a flexible, non-stretchable tape. Among participants with obesity (GNHIES98) and par-
ticipants with no visible waist (DEGS1) WC was measured at the midpoint between the lowest
rib and the ileac crest.
Self-reported physician-diagnosed diabetes, hypertension, and dyslipidaemia were obtained
in computer-assisted interviews administered by specifically trained study physicians. All med-
ications taken in the seven days prior to the interview were documented by trained medical
staff. Medications were coded according to the Anatomical Therapeutic Chemical classifica-
tion system and categorized as any lipid-lowering (C10), antihypertensive (C02, C03, C07,
C08, C09), and antidiabetic medication (A10).
Blood samples were taken at the study centres, processed within one hour, and stored at
-40˚C. The fasting period was documented for every participant. Fasting instructions changed
between surveys. Blood samples were taken over the day in GNHIES98 [23]. In DEGS1, partic-
ipants were specifically asked to keep an overnight fasting period of at least eight hours for
morning appointments and of at least four hours for afternoon appointments, unless they had
diagnosed diabetes [24]. Consequently, a significantly higher proportion of study participants
had fasting blood samples in DEGS1 compared to GNHIES98 [18]. A fasting period less than
eight hours was categorized as non-fasting. Laboratory analyses were conducted at the Robert
Koch Institute Central Epidemiological Research Laboratory. In GNHIES98 glycated haemo-
globin (HbA1c) was determined by a Diamant high performany liquid chromatography analy-
ser (Bio-Rad, Germany) using reagents from Recipe (Recipe Chemicals and Instruments,
Munich) and in DEGS1 by an immunoturbidimetric method (Architect ci8200). Measure-
ments from both methods were traceable to the National Glycohemoglobin Standardization
Program reference and the distribution of HBA1c measures among metabolically healthy sub-
groups of normoglycaemia did not change over time [26]. Serum lipid levels were determined
by an enzymatic procedure, based on the cholesterol oxidase-peroxidase 4-aminophenazone
method (high density lipoprotein-cholesterol, HDL-C) and the glycerol-3-phosphate oxidase-
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peroxidase 4-aminophenazone method (GPO-PAP; triglycerides). While the principle of mea-
surement remained the same, the analyser for serum lipids changed during the surveys
(GNHIES98: MEGA, Merck, Germany; DEGS1: Architect ci2800, Abbott, Germany). A small
impact cannot be excluded, but previous analyses do not suggest substantial measurement
error [18].
Blood pressure was measured on the right arm following a standardized protocol and using
either a standard mercury sphygmomanometer (GNHIES98) or an automated oscillometric
device (Datascope Accutorr Plus, DEGS1). The blood pressure values of GNHIES98 were cor-
rected by a calibration formula validated for DEGS1 [27].
Definition of metabolic health and body size category
We defined MH using two different established algorithms, which were applicable to our sur-
vey data. First, we defined MH by the absence of the MetS based on the National Cholesterol
Education Program ATP III criteria [28] as used by van Vliet-Ostaptchouk et al. [29]. Accord-
ing to this algorithm, MH is present among persons fulfilling at least three out of five criteria
as listed in Table 1. Use of any antidiabetic, antihypertensive or lipid-lowering medication as
well as history of physician-diagnosed diabetes, hypertension and dyslipidaemia is additionally
considered and counted as not fulfilling the respective criterion. Secondly, MH was defined
using the criteria proposed by Plourde and Karelis (PK criteria) [30]. These provide a consid-
erably more stringent algorithm to define MH, as they include lower thresholds for blood pres-
sure and require fulfilment of all of the four proposed criteria. Because fasting instructions
changed between GNHIES98 and DEGS1 we used HbA1c, which is independent of fasting
time, instead of serum glucose. Different cut-offs for triglycerides were used among fasting
and non-fasting participants as described by van Vliet-Ostaptchouk et al. [29].
Body size categories were defined as BMI categories of normal weight (BMI< 25 kg/m),
pre-obesity (25 kg/m BMI< 30 kg/m), and obesity (BMI 30 kg/m) according to WHO rec-
ommendations [31] or WC categories indicating individuals without abdominal obesity
(WC< 80 cm among women and WC< 94 cm among men) and those with abdominal obesity
(WC 80 cm among women and WC 94 cm among men) [30].
Analysis
In cross-sectional survey-specific analyses means, percentages and 95% confidence intervals
were calculated sex-specifically and for men and women combined. The proportion of persons
with MH across BMI categories were assessed using ATPIII criteria, whereas WC categories
Table 1. Definition of metabolic health.
ATPIII criteria Plourde and Karelis criteria
Waist
circumference
< 88 cm (women) or 102 cm (men) -
HbA1c < 5.7% [32] and no diagnosis of diabetes and no use of antidiabetic
medications
< 5.7% [32] and no diagnosis of diabetes and no use of antidiabetic
medications
Blood pressure < 130/85 mmHg and no diagnosis of hypertension and no use of
antihypertensive medication




Fasting triglycerides< 1.7 mmol/l or non-fasting triglycerides< 2.1
mmol/l [29] and no diagnosis of dyslipidaemia and no use of lipid-
lowering medication
Fasting triglycerides< 1.7 mmol/l or non-fasting triglycerides< 2.1
mmol/l [29] and no diagnosis of dyslipidaemia and no use of lipid-
lowering medication
HDL-C  1.03 mmol/l (men) or 1.30 mmol/l (women)  1.03 mmol/l (men) or 1.30 mmol/l (women)
Metabolic health At least three criteria fulfilled All criteria fulfilled
doi:10.1371/journal.pone.0167159.t001
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were applied in relation to the PK criteria of MH. Differences in the proportions of MH by
body size categories between the two survey periods were tested using the Rao-Scott chi-square
test. In a sensitivity analysis we excluded WC from the definition of MH by ATPIII criteria
(two out of four criteria fulfilled) as done in previous studies [29, 32]. The proportion of MH
by body size categories in 1997–99 and 2008–11 was also calculated stratified for age (18–44,
45–64, and 65–79 years).
All statistical analyses were performed using survey procedures for complex samples in SAS
9.4 (SAS Institute, Cary, NC). To account for the unequal sampling probabilities, the statistical
analyses were weighted. The weighting factor for DEGS1 was calculated in two steps [25].
First, design weights were calculated separately for first-time participants and re-participants.
The weighting factor for re-participants was the inverse participation probability in DEGS1
(product of the probability of having participated in GNHIES98 and the probability to partici-
pate again in DEGS1). In the second step, both design weights were adjusted to the population
structure in Germany on 31.12.2010 with regard to age, sex, educational status, federal state,
and type of municipality. Results for GHNIES98 were adjusted to the population structure on
31.12.1997. For analysis of differences in proportions over time, the GNHIES98 results were
age-standardized to the population on 31 December 2010. P values were calculated based on
two-sided tests. Bonferroni-Holm correction (α = 0.05) was used to reduce the chances of
obtaining false-positive results (type 1 errors). With regard to multiple comparisons each p
value< 0.001 was considered statistical significant.
Results
The study characteristics of GNHIES98 and DEGS1 are presented in Table 2. More partici-
pants in DEGS1 fasted longer than eight hours before blood sampling. Compared to partici-
pants of GNHIES98 those of DEGS1 had a higher prevalence of obesity based on BMI, which
was due to increases among men. In contrast, the prevalence of abdominal obesity decreased
among men. Participants in DEGS1 showed also changes in a number of cardio-metabolic cri-
teria compared to GNHIES98 participants, including a higher proportion of men with low risk
triglyceride levels, high HDL-C levels and a higher proportion of women with very low risk
blood pressure and low risk HbA1c levels. In contrast, a lower proportion of men had low risk
blood pressure in DEGS1 compared to GNHIES98.
From GNHIES98 to DEGS1 proportions of persons with MH were unchanged among all
categories of body size (Table 3), except a small increase in MH among persons with pre-obe-
sity (65 to 69%) and among women without abdominal obesity (38 to 43%). In sensitivity anal-
yses excluding WC from the ATPIII criteria no changes in MH were found in all BMI
categories between GNHIES98 and DEGS1 (S1 Table). Proportions were substantially and
consistently lower applying the more stringent PK criteria as compared to the ATPIII criteria.
Proportions of persons with MH were consistently higher among normal weight compared to
persons with pre-obesity and obesity, as well as among persons without abdominal obesity
compared to participants with abdominal obesity. In both surveys the proportion of men and
women combined with obesity meeting ATPIII criteria was almost 30% and the proportion of
men and women with MH according to PK criteria was less than 10% among those with
abdominal obesity.
In age-specific analyses proportions of MH were consistently higher in younger compared
to older age groups (Table 4). There was an increase over time in the proportion of persons
with MH among 18–44 year-old men with obesity (33 to 52%) and 65–79 year-old women
with normal weight (62 to 79%), although the result was not statistically significant according
to the Bonferroni-Holm correction.
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Discussion
The proportion of MH persons with normal weight, obesity and abdominal obesity remained
unchanged between GNHIES98 and DEGS1 based on the original ATPIII and the PK criteria.
In contrast, there was a slight increase in the proportion of MH among persons with pre-obe-
sity and among women without abdominal obesity. Using the ATPIII criteria 93% of men and
women combined with normal weight, 69% with pre-obesity (65% in GNHIES98) and 32%
with obesity were MH in DEGS1. Using the more stringent PK criteria only 31% of persons
without abdominal obesity (28% in GNHIES98) and 8% of persons with abdominal obesity
were MH in DEGS1. In accordance with previous studies [29, 33], a higher proportion of MH
was found among women compared to men.
The increasing proportion of MH among persons with pre-obesity and women with
abdominal obesity are in line with the favourable changes in health-related behaviour in the
German population between GNHIES98 and DEGS1. During this period, the prevalence of
sports activity [15] and fruit intake increased [17], whereas the prevalence of smoking [16] and
Table 2. Characteristics of the study population by survey, National Health Interview and Examination Surveys for Adults in Germany 1997–99















Age (years; mean) 45.4 (44.8–46.1) 47.3 (46.8–
47.8)
.850 44.4 (43.6–45.2) 46.9 (46.2–
47.5)
.860 46.4 (45.7–47.1) 47.8 (47.1–
48.4)
.890
Fasting duration 8 hours (%) 26.5 (25.1–28.1) 48.0 (46.5–
49.5)
< .001 22.9 (20.9–24.9) 50.2 (48.2–
52.3)




Underweight (BMI< 18.5 kg/m, N) 59 91 12 24 47 67
Normal weight (BMI< 25 kg/m, %) 39.3 (37.5–41.2) 40.2 (38.5–
41.8)
< .001 32.3 (30.0–34.6) 32.9 (30.9–
35.0)
< .001 46.3 (44.0–48.6) 47.4 (45.2–
49.6)
.110
Pre-obesity (25 BMI< 30 kg/m, %) 39.6 (38.2–41.0) 36.4 (35.1–
37.7)
48.6 (46.6–50.6) 43.6 (41.6–
45.6)
30.7 (29.0–32.4) 29.2 (27.5–
31.0)
Obesity (BMI 30 kg/m, %) 21.1 (19.6–22.7) 23.5 (21.9–
25.0)
19.1 (17.6–20.8) 23.5 (21.4–
25.7)
23.0 (21.0–25.1) 23.4 (21.5–
25.5)
Abdominal obesity (waist
circumference 80/94 cm a, %)
58.6 (56.6–60.5) 55.6 (53.5–
57.5)
< .001 57.6 (55.2–60.0) 54.2 (51.7–
56.6)




Waist circumference< 88/102 cma 66.1 (64.3–67.9) 66.1 (64.2–
68.0)
.110 70.5 (68.4–72.5) 68.7 (66.3–
70.9)
.690 61.7 (59.4–64.0) 63.6 (61.1–
66.1)
.025
Low risk HbA1c (< 5.7%)b 65.1 (62.7–67.5) 69.8 (66.6–
72.9)
< .001 62.5 (59.6–65.4) 65.4 (61.6–
69.0)
.032 67.7 (65.2–70.1) 74.2 (70.8–
77.3)
< .001
Very low risk blood pressure (< 120/80
mmHg)c
31.6 (29.8–33.5) 32.0 (30.5–
33.5)
.013 24.4 (22.4–26.5) 20.5 (18.8–
22.3)
.110 38.8 (36.3–41.2) 43.4 (41.3–
45.5)
< .001
Low risk blood pressure (< 130/85
mmHg)c
53.9 (52.0–55.8) 48.7 (47.3–
50.1)
.029 51.3 (48.8–53.8) 41.5 (39.4–
43.6)
< .001 56.5 (54.4–58.6) 55.9 (53.9–
57.8)
.170
Low risk triglyceridesd 59.2 (57.7–60.8) 60.2 (58.8–
61.5)
.005 51.9 (49.6–54.2) 54.6 (52.6–
56.6)
< .001 66.5 (64.4–68.5) 65.7 (63.8–
67.6)
.540
High HDL-C ( 1.30/1.03 mmol/l)a 74.6 (73.0–76.2) 79.5 (77.6–
81.3)
< .001 72.9 (70.8–74.9) 82.3 (80.0–
84.3)
< .001 76.4 (74.2–78.4) 76.8 (74.3–
79.1)
.750
Due to Bonferroni-Holm correction p values < 0.01 were considered statistically significant (bold).
a women/men.
b and no diagnosis of diabetes and no antidiabetic medication.
c and no diagnosis of hypertension and no antihypertensive medication.
d fasting triglycerides< 1.7 mmol/l (2.1 mmol/l among individuals who fasted less than eight hours) and no diagnosis of dyslipidaemia and no lipid-lowering
medication.
doi:10.1371/journal.pone.0167159.t002
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mean serum lipid levels decreased [18]. An improvement in MH among all anthropometric
categories was found between 1986 and 2009 in northern Sweden (MONICA study; Multina-
tional MONItoring of trends and determinants in CArdiovascular disease) [34]. In this study
population, improved MH defined by normal blood pressure (< 140/90 mmHg), normal cho-
lesterol (< 5.0 mmol/l) and no known diabetes. However, increased prevalence of MH was not
consistently found in all sex and weight strata over the entire study period.
We found a higher proportion of MH among younger age groups. Aging is associated with
the conversion from the MH to the MU subgroup as seen in longitudinal studies indicating
that not all MH individuals remain healthy over time [35, 36]. This is partly due to the fact that
weight gain and changes to a less favourable behavioural pattern all become more likely with
increasing age [35]. The duration of overweight also plays an important role in the progression
of CVD risk factors [37].
Multiple comparisons enhance the chance to obtain a false-positive finding. To reduce this
chance we corrected for multiple testing using the Bonferroni-Holm method. On the other
Table 3. Proportion (%) of metabolically healthy persons by body size categories and survey, National Health Interview and Examination Surveys
















Normal weight 92.3 (91.0–93.4) 93.0 (91.6–
94.1)
.033 90.5 (88.4–92.3) 91.7 (89.2–
93.7)
.081 93.5 (91.8–94.8) 93.9 (92.2–
95.2)
.200




66.8 (63.8–69.7) 69.0 (66.0–
71.8)
.011 63.2 (60.2–66.1) 68.1 (64.5–
71.4)
.004
Obesity 26.3 (22.9–30.0) 32.0 (28.9–
35.4)
.002 23.5 (19.2–28.4) 30.6 (26.1–
35.4)
.014 28.6 (24.0–33.7) 33.5 (29.5–
37.8)
.033
Plourde and Karelis criteria
No abdominal
obesity
27.8 (25.6–30.1) 30.9 (28.7–
33.3)
.003 18.0 (15.7–20.7) 19.2 (16.6–
22.2)




Abdominal obesity 7.7 (6.7–8.9) 7.6 (6.4–8.9) .480 3.9 (2.9–5.3) 3.6 (2.6–5.1) .870 11.4 (9.8–13.2) 11.3 (9.6–13.3) .550
Due to Bonferroni-Holm correction p values < 0.01 were considered statistically significant (bold).
doi:10.1371/journal.pone.0167159.t003
Table 4. Proportion (%) of metabolically healthya persons by body mass index and survey, National Health Interview and Examination Surveys for
Adults in Germany 1997–99 (GNHIES98) and 2008–11 (DEGS1) stratified by age group.
18–44 years 45–64 years 65–79 years
GNHIES98 DEGS1 P GNHIES98 DEGS1 P GNHIES98 DEGS1 P
Men N = 1608 N = 1158 N = 1197 N = 1250 N = 400 N = 890
Normal weight 95.7 (93.4–97.2) 95.8 (92.7–97.6) .890 81.5 (75.7–86.1) 88.4 (82.8–92.3) .090 64.7 (51.6–75.9) 72.8 (63.1–80.7) .270
Pre-obesity 81.9 (78.0–85.2) 83.2 (78.0–87.4) .420 58.6 (53.4–63.6) 68.7 (64.4–72.7) .006 42.8 (36.0–49.9) 44.5 (38.5–50.5) .560
Obesity 32.8 (25.1–41.6) 51.5 (42.8–60.0) .003 19.2 (14.4–25.1) 26.2 (20.5–32.7) .120 10.9 (5.9–19.3) 11.5 (6.9–18.6) .780
Women N = 1624 N = 1260 N = 1245 N = 1422 N = 491 N = 880
Normal weight 98.3 (96.8–99.1) 98.8 (97.3–99.5) .390 90.2 (86.4–93.1) 89.6 (85.8–92.4) .700 61.7 (51.3–71.0) 78.5 (70.7–84.7) .007
Pre-obesity 89.3 (85.9–92.0) 92.8 (88.6–95.5) .100 60.4 (55.6–65.1) 69.6 (64.3–74.4) .036 31.3 (25.0–38.3) 35.1 (28.8–42.0) .410
Obesity 52.5 (43.2–61.6) 60.6 (51.2–69.3) .230 23.1 (18.6–28.3) 32.2 (26.9–38.0) .021 11.9 (6.7–20.5) 15.3 (11.0–20.9) .410
Due to Bonferroni-Holm correction p values < 0.01 were considered statistically significant (bold).
a defined by ATPIII criteria.
doi:10.1371/journal.pone.0167159.t004
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hand, the correction for multiple testing increases the type II error (false-negative finding)
[38]. Although the hypothesis of increasing MH among young men with obesity was rejected
due to the Bonferroni-Holm correction, the results are in line with previous findings regarding
the transition of the MH group. Previous studies do not demonstrate a greater improvement
in health-behaviour among young men than among men at older ages [15–17]. This suggests
that the increase in MH among 18–44 year-old men with obesity are due to the increased prev-
alence of obesity among this age group [2]. The duration of obesity has great impact on the
metabolic profile and the increased proportion of MH among this group may be attenuated
after the inclusion of information on obesity duration. Unfortunately, information on obesity
duration was not available in the present study.
There is ongoing debate on how to define the MH subgroup [8]. The risk for CVD and
mortality is already increased with the presence of one component of the MetS [39]. In this
context, the PK criteria, which define MH by the fulfilment of all included criteria may be
more appropriate to determine “true” MH [30] than the ATPIII criteria, which define MH
when at least three criteria are fulfilled. Among other factors, MH status is affected by body fat
distribution [7]. The BMI is probably not the ideal measure of obesity, since it does not dis-
criminate between fat and lean body mass [40]. Therefore persons may be misclassified when
BMI is used to define body size. WC is correlated with visceral adipose tissue and, as suggested
by Plourde and Karelis [30], might be more appropriate to define MH body size groups. How-
ever, also WC does not account for body fat distribution in general [40].
The major limitation of this study was that blood sampling was not generally conducted
in a fasting state. Thus, we used HbA1c instead of serum glucose and different cut-offs
among fasting and non-fasting participants for triglycerides. Nevertheless, the decrease in
the prevalence of low risk triglycerides may be overestimated. However, previous analyses
of our data have shown that the decline in triglyceride levels persisted after adjusting for
age and fasting period [18]. An additional limitation is that the WC measurement instruc-
tions slightly changed between the two German national health surveys; hence we cannot
exclude misclassification bias, with overestimation of abdominal obesity in GNHIES98
compared to DEGS1. The slight increase in MH among persons with pre-obesity might be
partially due to this change, since no significant change in MH was found in a sensitivity
analysis excluding WC from the ATPIII criteria. The DEGS1 sample comprises first-time
participants and re-participants of GNHIES98, which might differ in several aspects. Thus,
we used weighting factors that account for this issue as well as for the complex sampling
design and non-response. However, bias caused by the DEGS1 study design cannot be
ruled out completely.
Conclusion
In summary, proportions of adults with MH by body size categories were largely stable
over time, except for an increasing proportion of MH women without abdominal obesity.
Thus, the proportion of MH among people with obesity in Germany did not change over a
period of ten years. Proportions of adults with MH vary according to body size and the MH
criteria applied.
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